ADMA Biologics Inc (ADMA) vs NewAmsterdam Pharma Company N.V. (NAMS)
- ADMA Biologics Inc ADMA 10.68 −0.47%
- NewAmsterdam Pharma Company N.V. NAMS 19.83 −3.83%
ADMA Biologics Inc and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. ADMA Biologics Inc and NewAmsterdam Pharma Company N.V. are of similar size ($2.5B and $2.4B). NewAmsterdam Pharma Company N.V. has negative trailing earnings, so its P/E is not meaningful; ADMA Biologics Inc trades at 14.8×. ADMA Biologics Inc grew revenue faster over the last twelve months: 8.04% against −88.9%. ADMA Biologics Inc has the higher net margin (33.0% vs −3,644.2%) and the higher return on invested capital (29.8% vs 0.00%). Across the 17 metrics below, ADMA Biologics Inc leads on 12 and NewAmsterdam Pharma Company N.V. on 5.
Valuation
Profitability
| Metric | ADMA | NAMS | Biotechnology median |
|---|---|---|---|
| Gross margin | 64.71% | 100.00% | 65.16% |
| Operating margin | 43.82% | (3,432.20%) | 0.00% |
| Net margin | 32.98% | (3,644.21%) | 0.00% |
| Free cash flow margin | 22.69% | (2,018.28%) | 0.00% |
| Return on equity | 41.90% | (36.81%) | (56.36%) |
| Return on assets | 27.19% | (34.16%) | (48.04%) |
| Return on invested capital | 29.78% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack